How Goes the War on Drugs?: OP-121-DPRC (häftad)

Fler böcker inom

Format: Häftad (Paperback / softback)
Språk: Engelska
Antal sidor: 64
Utgivningsdatum: 2005-03-01
Upplaga: illustrated ed
Förlag: RAND
Medarbetare: Reuter, Peter
Illustratör/Fotograf: Illustrations
Illustrationer: Illustrations
Volymtitel: OP-121-DPRC
Dimensioner: 280 x 216 x 3 mm
Vikt
Antal komponenter: 1
Komponenter: 1412:Standard Color 8.5 x 11 in or 280 x 216 mm Perfect Bound on White w/Matte Lam
ISBN: 9780833037374

How Goes the War on Drugs?: OP-121-DPRC

An Assessment of U.S. Drug Problems and Policy

av Jonathan P Caulkins, Peter Reuter, Martin Y Iguchi, James Chiesa

Häftad, Engelska, 2005-03-01

227

Köp

Spara som favorit

Specialorder (osäker tillgång). Skickas från oss inom 11-20 vardagar.
Fri frakt över 249 kr för privatkunder i Sverige.

Kan tyvärr inte levereras innan julafton.

Köp ett presentkort istället.

Presents a concise, accessible, objective view of where the United States has been, now stands, and is going in the future in its long "war on drugs." The authors assess the success of drug policies to date and review possible reasons why they have not been more successful. They recommend management of the drug problem for the long term, use of different policy levers depending on the situation, and tolerance of cross-state policy variation.

Visa hela texten

Passar bra ihop

De som köpt den här boken har ofta också köpt Oath and Honor av Liz Cheney (häftad).

Köp båda 2 för 414 kr

Marijuana Legalization

Jonathan P Caulkins

214

Köp

Skickas inom vardagar.
Crime and Justice, Volume 49 Organizing Crime: Mafias, Markets, and Networks

Michael Tonry, Peter Reuter, Peter Reuter

1063

Köp

Skickas inom vardagar.
Draining Development?

Peter Reuter

657

Köp

Skickas inom vardagar.
Chasing Dirty Money - The Fight Against Money Laundering

Peter Reuter, Edwin M Truman

220

Köp

Skickas inom vardagar.

Presents an objective view of where the US has been, now stands, and is going in the future in its "war on drugs." The authors assess the success of drug policies to date and review reasons why they have not been more successful.